



ISLHD CLINICAL TRIALS

Shoalhaven Cancer Care Centre

June 2024

ISLHD CANCER CLINICAL TRIALS UNIT

**Shoalhaven Cancer Care
Centre**

**Shoalhaven District
Memorial Hospital**

**Corner of Scenic Drive &
North Street
Nowra NSW 2541**

Ph: 02 4253 4384

Fax: 02 4222 5085

**Email: ISLHD-
CancerClinicalTrials@health.
nsw.gov.au**

The Illawarra Shoalhaven Local Health District (ISLHD) Cancer Clinical Trials Unit has a specialist team of doctors, nurses, radiation therapists and allied health professionals supporting a comprehensive suite of clinical trials for our local community. We are based at Wollongong and Shoalhaven District Memorial Hospitals in the Illawarra Cancer Care Centre and Shoalhaven Cancer Care Centre.

Clinical trials contribute to evidence based practice, knowledge development and improved patient care. They provide our patients the opportunity to access novel and potentially efficacious treatment for their cancer close to home.

We currently have trials open for patients with:

- Colorectal cancer
- Gynaecological neoplasms
- Skin cancer
- Multiple Myeloma





REFERRAL OR CONSULTATION

To discuss your patient with an ISLHD Trials Clinician, please phone the Shoalhaven Cancer Care Centre on
02 4428 7400

ISLHD Clinical Trials

CURRENTLY OPEN FOR RECRUITMENT

Scan the QR Code for more information including eligibility criteria

GI/Biliary	OXTOX: Can oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study. **Closing soon**	Prof Chantrill *Satellite site	
Gynae	PARAGON-II: Phase II basket study of an Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic Gynaecological Neoplasms. **Cohorts A, B, D, E, F (limited spots) only**	Dr Kasherman *Satellite site	
Skin	CPOST: A randomised, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.	A/Prof Brungs *Satellite site	
Multiple Myeloma	CA057-001: A Phase 3, Two-Stage, Randomized, Multi-center, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVD) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) **Part 2 now open for enrolment**	Dr Parmar *Satellite site	

For further information regarding these trials at the Shoalhaven Cancer Care Centre you may also contact the trial coordinators as listed or email ISLHD-SCCC-CancerClinicalTrials@health.nsw.gov.au

Trial Coordinator	Availability	Contact details
Kyrie Rodgers	Mon-Thurs	02 4428 7516
Rachael Dunster	Tues, Thurs, Fri	02 4429 1676
Jamie Tomlinson [maternity leave from Nov 2023]	Wed-Fri	02 4429 1676